Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E31.39 EPS (ttm)1.61 Insider Own0.10% Shs Outstand1.66B Perf Week-2.75%
Market Cap83.77B Forward P/E29.09 EPS next Y1.74 Insider Trans-8.80% Shs Float1.66B Perf Month-0.10%
Income2.69B PEG2.37 EPS next Q0.42 Inst Own71.60% Short Float1.94% Perf Quarter4.75%
Sales16.21B P/S5.17 EPS this Y32.80% Inst Trans-0.27% Short Ratio5.66 Perf Half Y-1.33%
Book/sh9.25 P/B5.46 EPS next Y-3.07% ROA7.60% Target Price53.00 Perf Year10.06%
Cash/sh4.33 P/C11.68 EPS next 5Y13.25% ROE17.70% 52W Range45.11 - 56.66 Perf YTD-3.55%
Dividend1.44 P/FCF68.28 EPS past 5Y-3.60% ROI10.70% 52W High-10.82% Beta0.40
Dividend %2.85% Quick Ratio1.60 Sales past 5Y-1.50% Gross Margin73.30% 52W Low12.01% ATR0.77
Employees28000 Current Ratio1.80 Sales Q/Q-3.90% Oper. Margin22.30% RSI (14)46.43 Volatility1.88% 1.47%
OptionableYes Debt/Eq0.50 EPS Q/Q-37.50% Profit Margin16.60% Rel Volume1.07 Prev Close51.18
ShortableYes LT Debt/Eq0.48 EarningsOct 24 BMO Payout87.10% Avg Volume5.69M Price50.53
Recom2.40 SMA20-1.02% SMA500.33% SMA2000.09% Volume6,084,450 Change-1.27%
25-Jul-14Reiterated MKM Partners Sell $29 → $34
15-Jan-14Reiterated Argus Buy $58 → $62
10-Jan-14Upgrade Barclays Equal Weight → Overweight $52 → $65
20-Dec-13Reiterated UBS Neutral $48 → $54
29-Jul-13Reiterated Argus Buy $54
17-Jul-13Reiterated Barclays Equal Weight $42 → $45
04-Jun-13Reiterated Argus Buy $46 → $54
26-Apr-13Reiterated MKM Partners Sell $26 → $29
15-Apr-13Reiterated Barclays Equal Weight $33 → $42
25-Jan-13Reiterated UBS Neutral $34 → $36
09-Jan-12Reiterated Barclays Capital Overweight $34 → $36
19-Oct-11Initiated MKM Partners Sell $26
27-Jun-11Reiterated UBS Neutral $28 → $30
31-Mar-11Downgrade Jefferies Buy → Hold $28.50
28-Mar-11Reiterated Barclays Capital Overweight $28 → $30
22-Sep-10Reiterated Deutsche Bank Buy $28 → $31.50
01-Sep-10Reiterated UBS Neutral $26 → $27
31-Aug-10Upgrade Jefferies Hold → Buy $28.80 → $30
12-Mar-10Initiated Jefferies & Co Hold $27
16-Dec-09Initiated UBS Neutral
01-Oct-14 04:00PM  Bristol-Myers' Opdivo under Review in EU for Lung Cancer Zacks
03:30PM  AbbVie Announces Positive Results on Oncology Candidate Zacks
11:57AM  [$$] Immuno-Oncology Agents Get Another Boost at Barrons.com
10:00AM  Bristol-Myers Squibb to Announce Results for Third Quarter on October 24 Business Wire
08:50AM  Abbott Labs Completes CFR Pharmaceuticals Acquisition Zacks
08:28AM  INNATE PHARMA : INITIATION OF A PHASE I CLINICAL TRIAL OF LIRILUMAB IN COMBINATION WITH ELOTUZUMAB Thomson Reuters ONE
08:00AM  Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance GlobeNewswire
30-Sep-14 05:45PM  [$$] Bristol-Myers Squibb to Transfer $1.4 Billion in U.S. Pension Obligations at The Wall Street Journal
05:00PM  Bristol-Myers Squibb to Transfer $1.4 Billion in U.S. Pension Obligations to Prudential Business Wire
11:10AM  Valeant's Bausch + Lomb Announces Results on Lotemax Zacks
29-Sep-14 05:50PM  Bristol-Myers' Opdivo Under Review in US, EU for Cancer Treatment Zacks
03:35PM  Novartis Gives Updates on Signifor LAR and Secukinumab Zacks
01:28PM  How to play volatility CNBC
01:28PM  [video] How to play volatility at CNBC
11:14AM  Cancer drug stocks on the move amid striking data at CNBC
08:21AM  European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer Business Wire
08:11AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers, Johnson & Johnson, AbbVie and Medivation Zacks
03:00AM  Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor Business Wire
03:00AM  Bristol immune drug shows strong effect in melanoma study Reuters
26-Sep-14 05:26PM  Fast Money Final Trade: XOM, HYG, YHOO & BMY CNBC
05:26PM  [video] Fast Money Final Trade: XOM, HYG, YHOO & BMY at CNBC
05:08PM  Bristol immunotherapy gets 6-month U.S. FDA review for melanoma Reuters
04:18PM  Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union Business Wire
03:30PM  Gilead's HIV Drugs Tybost and Vitekta Get FDA Clearance Zacks
01:04PM  BMY, MRK And PFE, 3 Drugs Stocks Pushing The Industry Lower at TheStreet
25-Sep-14 06:57PM  Cramer's Remix: Selloff strategies to survive drop at CNBC
06:28PM  Cramer's Bristol-Myers theorem: What is it? at CNBC
01:33AM  INNATE PHARMA: Third DSMB for EffiKIR trial recommends continuation as planned Thomson Reuters ONE
24-Sep-14 05:29PM  Gilead's New HIV Drug Key To Long-Term Strategy at Investor's Business Daily
22-Sep-14 08:00AM  Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers Business Wire
19-Sep-14 05:04PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia EDGAR Online
04:40PM  Bristol-Myers' (BMY) Yervoy Label Expanded in Canada Zacks
18-Sep-14 03:55PM  Merck Enters into Licensing Agreement with Sun Pharma Zacks
17-Sep-14 05:13PM  [$$] Bristol-Myers CEO Sells $2.5 Million in Stock at Barrons.com
16-Sep-14 04:30PM  Bristol-Myers Squibb Announces Dividend Business Wire
08:10AM  What Ralph Nader Gets Wrong About Big Pharma at Forbes
08:10AM  Ralph Nader Has Set His Sights On Big Pharma -- And He Misses Opportunity at Forbes
05:59AM  Health Canada approves Yervoy® (ipilimumab) for first-line treatment of adults with metastatic melanoma, the most deadly form of skin cancer CNW Group
15-Sep-14 11:35AM  Video: Gilead OKs Generic Sovaldi To Expand Access at Investor's Business Daily
11:35AM  Gilead OKs Generic Sovaldi To Expand Global Access at Investor's Business Daily
12-Sep-14 08:43AM  Up and Down the Ladder: The Latest Comings and Goings at FDA, Cardinal Health and at The Wall Street Journal
11-Sep-14 11:30AM  Insider Trading Alert - BMY, AMBA And MTD Traded By Insiders at TheStreet
10:00AM  Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference Business Wire
09-Sep-14 06:00AM  Bristol-Myers Needs a Healthy Growth Shot to Justify Its Valuation at TheStreet
08-Sep-14 06:24PM  Bristol-Myers, Ono Sue Merck Over Cancer-Drug Patent at The Wall Street Journal
03:30PM  Bristol-Myers Sues Merck of Patent Infringement on Keytruda Zacks
11:11AM  [$$] A New Era in Immuno-Oncology at Barrons.com
10:18AM  Bristol-Myers Sues Merck Over a Patent on its new Cancer Drug at The Wall Street Journal
08:48AM  J.P. Morgan Biotech Analyst Meacham Exits for New Barclays Gig at TheStreet
06:14AM  Bristol-Myers bulls back for more optionMONSTER
01:11AM  Bristol-Myers, Ono Sue Merck Over Cancer-Drug Patent at The Wall Street Journal
12:15AM  Bristol-Myers, Ono Sue Merck Over Cancer-Drug Patent at The Wall Street Journal
05-Sep-14 09:25PM  Bristol-Myers sues Merck over U.S. immunotherapy patent Reuters
04:04PM  Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug Benzinga
02:12PM  Bristol-Myers Sues Merck Over Cancer Immunotherapy Patent at Bloomberg
10:20AM  Merck's Anti-PD-1 Drug Keytruda First to be Launched in US Zacks
06:14AM  Bristol-Myers bulls looking for rally optionMONSTER
04-Sep-14 04:33PM  Merck PD-1 Inhibitor Approved For Skin Cancer at Investor's Business Daily
03:44PM  U.S. approves Merck immune-stimulating drug for melanoma Reuters
12:11AM  [$$] Powerful New Cancer Drugs Offer Hopeat Steep Cost at The Wall Street Journal
03-Sep-14 11:12PM  [$$] Powerful New Cancer Drugs Offer Hopeat Steep Cost at The Wall Street Journal
09:48PM  [$$] Powerful New Cancer Drugs Offer Hopeat Steep Cost at The Wall Street Journal
09:16PM  [$$] Powerful New Cancer Drugs Offer Hopeat Steep Cost at The Wall Street Journal
08:45PM  [$$] Powerful New Cancer Drugs Offer Hopeat Steep Cost at The Wall Street Journal
08:01PM  [$$] New Cancer Drugs Offer Hope---at Steep Cost at The Wall Street Journal
04:22PM  Drug M&A Boom Driven By Long-Term Trends: PwC at Investor's Business Daily
10:45AM  Credit Suisses 4 Top Pharmaceutical Stocks to Buy for the Rest of 2014 24/7 Wall St.
10:02AM  Bristol-Myers Returns Clazakizumab Rights, Alder Sinks Zacks
02-Sep-14 05:50PM  Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis Zacks
05:42PM  Booming Biotech Market Benefits REIT BioMed Realty at Investor's Business Daily
10:58AM  Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference Business Wire
01-Sep-14 03:27AM  Novartis Rises Most in Five Months on Heart-Drug Trial at Bloomberg
30-Aug-14 07:00AM  New Novartis Drug Effective in Treating Heart Failure at New York Times
05:15AM  Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) Business Wire
29-Aug-14 03:30PM  Eli Lilly-Boehringer Drug's Cost Effectiveness Questioned Zacks
28-Aug-14 05:50PM  Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance Zacks
08:20AM  The Zacks Analyst Blog Highlights: InterMune, Kite Pharma, Amicus, Celgene and Bristol-Myers Squibb Zacks
27-Aug-14 12:03PM  Bristol-Myers Hepatitis C Therapy Approved in EU at Investor's Business Daily
11:34AM  [video] Facebook and Movado Downgraded, Deutsche Initiates Drugmakers at TheStreet
09:27AM  Will This Coverage Initiation Affect Bristol-Myers Squibb (BMY) Stock Today? at TheStreet
06:53AM  [$$] Bristol-Myers Hepatitis C Drug Approved in Europe at The Wall Street Journal
05:00AM  European Commission Approves Bristol-Myers Squibbs Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection Business Wire
26-Aug-14 12:07PM  Merck, Pfizer Combining Drugs In Lung Cancer Study at Investor's Business Daily
25-Aug-14 10:58AM  There's still hunger for 'blockbuster' biotech deals at CNBC
22-Aug-14 04:55PM  Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod Zacks
21-Aug-14 04:20PM  Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments Zacks
04:07PM  FDA Grants New Indication For Pfizer, Bristol-Myers Squibb Drug at Forbes
03:47PM  5 companies that will benefit from ALS awareness at MarketWatch
03:10PM  FDA clears Eliquis for new use against blood clots AP
02:44PM  FDA approves use of Eliquis to treat leg, lung clots Reuters
02:44PM  ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms 24/7 Wall St.
01:56PM  FDA OKs use of Eliquis to treat leg, lung clots Reuters
01:31PM  U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy Business Wire
20-Aug-14 08:52AM  [$$] Bristol-Myers, Celgene to Collaborate on Cancer-Treatment Study at The Wall Street Journal
08:00AM  Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014 Business Wire
08:00AM  Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen Business Wire
19-Aug-14 06:27PM  This stock may be hazardous to your financial health Talking Numbers
18-Aug-14 08:00AM  Premier Biotechnology & Anti-CTLA4 Accesswire
12-Aug-14 10:48AM  Intercept Pharma Soars On Liver-Disease Drug Data at Investor's Business Daily
08-Aug-14 05:50AM  Cramer: The Futures Don't Discriminate TheStreet
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company's principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances and collaborations with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cuss Francis MEVP & CSOSep 16Option Exercise25.1763,6671,602,575302,113Sep 16 05:18 PM
Cuss Francis MEVP & CSOSep 16Sale50.7763,6673,232,074238,446Sep 16 05:18 PM
Caforio GiovanniChief Operating OfficerSep 15Sale49.8726,6911,331,15540,755Sep 16 05:18 PM
Caldarella Joseph CSVP & ControllerSep 10Sale51.037,415378,37761,550Sep 10 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerSep 08Sale51.0550,0002,552,430610,809Sep 10 04:30 PM
von Autenried PaulSVP, Enterp. Services & CIOAug 19Sale49.8920,000997,85137,523Aug 19 05:08 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Option Exercise27.0119,650530,74759,652Jul 30 04:40 PM
Moed Samuel JSVP, Strat Plan & AnalysisJul 28Sale49.3225,7521,270,03733,900Jul 30 04:40 PM
DANIELS BRIANSVP Global Dev & Med AffairsJul 01Option Exercise0.004,671096,477Jul 02 06:35 PM
ANDREOTTI LAMBERTOChief Executive OfficerMay 05Option Exercise0.0013,9900662,469May 06 09:17 PM
Elicker John ESVP Pub Affairs & Inv RelationMay 03Option Exercise0.001,509050,536May 05 05:05 PM
Moed Samuel JSVP, Strat Plan & AnalysisMay 01Option Exercise0.005,000042,595May 02 04:18 PM
JUDGE ANN POWELLSVP, Human ResourcesApr 01Option Exercise0.001,55403,693Apr 03 04:17 PM
Caldarella Joseph CSVP & ControllerMar 13Sale55.209,137504,36268,965Mar 13 04:32 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.002,739058,345Mar 12 04:54 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.004,8780262,120Mar 12 04:52 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.001,173037,948Mar 12 04:53 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.00688043,432Mar 12 04:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.002,739011,600Mar 12 04:53 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.002,7390239,268Mar 12 04:51 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 10Option Exercise0.002,528092,314Mar 12 04:51 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.001,850049,399Mar 12 04:52 PM
Heller Frances KSVP, Business DevelopmentMar 10Option Exercise0.001,60904,402Mar 12 04:52 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.002,10702,107Mar 12 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.006,4100165,472Mar 12 04:50 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 10Option Exercise0.004,878068,910Mar 12 04:51 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.001,850078,768Mar 12 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0027,6130658,396Mar 12 04:50 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Sale55.818,799491,0638,861Mar 10 04:43 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Sale55.52100,0005,552,260630,783Mar 10 04:40 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400738,383Mar 10 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230159,626Mar 10 04:40 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 06Option Exercise0.002,889064,586Mar 10 04:40 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931077,422Mar 10 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100237,106Mar 10 04:41 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528017,224Mar 10 04:43 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390056,064Mar 10 04:43 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043036,841Mar 10 04:42 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 06Option Exercise0.003,010090,018Mar 10 04:41 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043047,630Mar 10 04:42 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724042,756Mar 10 04:42 PM
CORNELIUS JAMES MDirectorMar 05Sale55.82100,0005,582,000273,393Mar 05 04:40 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 03Option Exercise0.0099,9370292,758Mar 05 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 03Option Exercise0.0015,209040,530Mar 05 04:39 PM
Nielsen AnneChief Compliance & Ethics OffMar 03Option Exercise0.0013,132046,648Mar 05 04:39 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 03Option Exercise0.0017,471051,061Mar 05 04:37 PM
Cuss Francis MEVP & CSOMar 03Option Exercise0.0047,9530254,899Mar 05 04:36 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 03Option Exercise0.0050,3260103,410Mar 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 03Option Exercise0.00121,0140199,850Mar 05 04:35 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 03Option Exercise0.0018,875068,527Mar 05 04:36 PM
Caldarella Joseph CSVP & ControllerMar 03Option Exercise0.0031,053089,900Mar 05 04:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 03Option Exercise0.00423,5330912,318Mar 05 04:35 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 03Option Exercise0.0039,420068,820Mar 05 04:40 PM
Schmukler Louis SPres., Global Mfg. & SupplyFeb 28Sale54.496,088331,73614,696Feb 28 04:44 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Option Exercise17.5139,363689,24691,316Feb 25 04:30 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Sale54.4441,5632,262,63849,753Feb 25 04:30 PM
Elicker John ESVP Pub Affairs & Inv RelationFeb 19Sale54.229,534516,91132,740Feb 19 04:25 PM
Cuss Francis MEVP & CSOFeb 18Option Exercise28.1138,6671,086,929237,037Feb 18 05:07 PM
Cuss Francis MEVP & CSOFeb 18Sale54.6129,8001,627,360207,237Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Option Exercise28.1115,000421,650206,345Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Option Exercise24.0036,251870,038130,266Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Sale54.2810,490569,377195,855Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Sale54.3552,9632,878,28577,303Feb 18 05:07 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Option Exercise28.11108,0003,035,880586,562Feb 11 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Sale52.6686,0754,532,572500,487Feb 11 04:30 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Option Exercise28.1118,750527,06381,989Feb 06 05:29 PM
Caldarella Joseph CSVP & ControllerFeb 06Option Exercise19.4226,484514,20294,826Feb 06 05:28 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Sale48.9328,4401,391,43353,549Feb 06 05:29 PM
Caldarella Joseph CSVP & ControllerFeb 06Sale48.9035,4711,734,45759,355Feb 06 05:28 PM
CAMPBELL LEWIS BDirectorFeb 05Option Exercise25.702,50064,2502,500Feb 05 05:37 PM
CAMPBELL LEWIS BDirectorFeb 05Sale48.282,500120,7120Feb 05 05:37 PM
CORNELIUS JAMES MDirectorFeb 04Sale48.90100,0004,890,000373,393Feb 04 05:00 PM
Caforio GiovanniEVP & Chief Commercial OfficerJan 03Option Exercise0.007,500054,817Jan 06 05:40 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660201,827Nov 04 04:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,869Oct 04 04:19 PM